News By Tag Industry News News By Place Country(s) Industry News
|  Now Available: Polycystic Ovarian Syndrome - Pipeline Review, H2 2012Recently published research from Global Markets Direct, "Polycystic Ovarian Syndrome - Pipeline Review, H2 2012", is now available at Fast Market Research
By: Fast Market Research, Inc. ------------------------------------------------------------ Full Report Details at - http://www.fastmr.com/ ------------------------------------------------------------ Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope * A snapshot of the global therapeutic scenario for Polycystic Ovarian Syndrome. * A review of the Polycystic Ovarian Syndrome products under development by companies and universities/ * Coverage of products based on various stages of development ranging from discovery till registration stages. * A feature on pipeline projects on the basis of monotherapy and combined therapeutics. * Coverage of the Polycystic Ovarian Syndrome pipeline on the basis of route of administration and molecule type. * Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress. * Key discontinued pipeline projects. * Latest news and deals relating to the products. Reasons to buy * Identify and understand important and diverse types of therapeutics under development for Polycystic Ovarian Syndrome. * Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. * Plan mergers and acquisitions effectively by identifying players with the most promising pipeline. * Devise corrective measures for pipeline projects by understanding Polycystic Ovarian Syndrome pipeline depth and focus of Polycystic Ovarian Syndrome therapeutics. * Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. * Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Keywords Polycystic Ovarian Syndrome Therapeutic Products under Development, Key Players in Polycystic Ovarian Syndrome Therapeutics, Polycystic Ovarian Syndrome Pipeline Overview, Polycystic Ovarian Syndrome Pipeline, Polycystic Ovarian Syndrome Pipeline Assessment Report Table of Contents: Table of Contents Table of Contents List of Tables List of Figures Introduction Global Markets Direct Report Coverage Polycystic Ovarian Syndrome Overview Therapeutics Development An Overview of Pipeline Products for Polycystic Ovarian Syndrome Polycystic Ovarian Syndrome Therapeutics under Investigation by Universities/ Late Stage Products Comparative Analysis Mid Clinical Stage Products Comparative Analysis Polycystic Ovarian Syndrome Therapeutics - Products under Investigation by Universities/ Polycystic Ovarian Syndrome - Therapeutics Assessment Assessment by Monotherapy Products Assessment by Combination Products Assessment by Route of Administration Assessment by Molecule Type Drug Profiles Metformin - Drug Profile Product Description Mechanism of Action R&D Progress Raloxifene - Drug Profile Product Description Mechanism of Action R&D Progress Letrozole - Drug Profile Product Description Mechanism of Action R&D Progress Human Chorionic Gonadotropin + Clomiphene Citrate - Drug Profile Product Description Mechanism of Action R&D Progress D-chiro-inositol - Drug Profile Product Description Mechanism of Action R&D Progress Simvastatin - Drug Profile Product Description Mechanism of Action R&D Progress Medroxyprogesterone - Drug Profile Product Description Mechanism of Action R&D Progress Polycystic Ovarian Syndrome Therapeutics - Drug Profile Updates Polycystic Ovarian Syndrome Therapeutics - Dormant Products Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer List of Tables Number of Products Under Development for Polycystic Ovarian Syndrome, H2 2012 Products under Development for Polycystic Ovarian Syndrome - Comparative Analysis, H2 2012 Number of Products under Investigation by Universities/ Comparative Analysis by Late Stage Development, H2 2012 Comparative Analysis by Mid Clinical Stage Development, H2 2012 Products under Investigation by Universities/ Assessment by Monotherapy Products, H2 2012 Assessment by Combination Products, H2 2012 Assessment by Stage and Route of Administration, H2 2012 Assessment by Stage and Molecule Type, H2 2012 Polycystic Ovarian Syndrome Therapeutics - Drug Profile Updates Polycystic Ovarian Syndrome Therapeutics - Dormant Products Polycystic Ovarian Syndrome Therapeutics - Dormant Products (Contd..1) List of Figures Number of Products under Development for Polycystic Ovarian Syndrome, H2 2012 Products under Development for Polycystic Ovarian Syndrome - Comparative Analysis, H2 2012 Products under Investigation by Universities/ Late Stage Products, H2 2012 Mid Clinical Stage Products, H2 2012 Assessment by Monotherapy Products, H2 2012 Assessment by Combination Products, H2 2012 Assessment by Route of Administration, H2 2012 Assessment by Stage and Route of Administration, H2 2012 Assessment by Molecule Type, H2 2012 Assessment by Stage and Molecule Type, H2 2012 About Global Markets Direct Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. End
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Account Phone Number